Essential thrombocythemia: Scientific advances and current practice

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose of review: Median survival in essential thrombocythemia exceeds 20 years and clinical course is usually indolent with a minority of patients experiencing thrombohemorrhagic complications. Leukemic, polycythemic, or fibrotic disease transformation in essential thrombocythemia is an infrequent occurrence with a 15-year cumulative risk of approximately 5% or less in each instance. The major incentives for this review have been the recent description of an activating JAK2 tyrosine kinase mutation (JAK2V617F) in essential thrombocythemia, related myeloproliferative disorders, and the impact on clinical practice from the publication of a major treatment trial. Recent findings: Several studies have reported on the occurrence of JAK2 V617F in approximately 50% of patients with essential thrombocythemia and its presence has been associated with advanced age at diagnosis, higher hemoglobin and leukocyte levels, and increased rate of polycythemic transformation. In contrast, the mutation did not appear to affect the incidence of thrombotic, leukemic, or fibrotic events. There is increasing evidence regarding the thrombogenic role of neutrophils in essential thrombocythemia and this might partly explain the superior overall performance by hydroxyurea, compared with anagrelide, in a recent randomized study. Summary: Although it is in vogue to consider essential thrombocythemia as more than one disease in terms of both molecular phenotype (presence or absence of JAK2V617F) and putative pattern of myelopoiesis (monoclonal versus polyclonal), it is yet to be shown that such differences influence either the natural history of the disease or current therapy. From a treatment standpoint, hydroxyurea is now confirmed to be the drug of choice for high-risk patients with essential thrombocythemia.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalCurrent Opinion in Hematology
Volume13
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Essential Thrombocythemia
Hydroxyurea
Myelopoiesis
Myeloproliferative Disorders
Mutation
Protein-Tyrosine Kinases
Publications
Motivation
Hemoglobins
Neutrophils
Leukocytes
Therapeutics
Phenotype
Survival
Incidence
Pharmaceutical Preparations

Keywords

  • Diagnosis
  • Hydroxyurea
  • JAK2
  • Thrombocythemia
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Essential thrombocythemia : Scientific advances and current practice. / Tefferi, Ayalew.

In: Current Opinion in Hematology, Vol. 13, No. 2, 03.2006, p. 93-98.

Research output: Contribution to journalArticle

@article{8ba4952528704688b74e370fbb06bc8a,
title = "Essential thrombocythemia: Scientific advances and current practice",
abstract = "Purpose of review: Median survival in essential thrombocythemia exceeds 20 years and clinical course is usually indolent with a minority of patients experiencing thrombohemorrhagic complications. Leukemic, polycythemic, or fibrotic disease transformation in essential thrombocythemia is an infrequent occurrence with a 15-year cumulative risk of approximately 5{\%} or less in each instance. The major incentives for this review have been the recent description of an activating JAK2 tyrosine kinase mutation (JAK2V617F) in essential thrombocythemia, related myeloproliferative disorders, and the impact on clinical practice from the publication of a major treatment trial. Recent findings: Several studies have reported on the occurrence of JAK2 V617F in approximately 50{\%} of patients with essential thrombocythemia and its presence has been associated with advanced age at diagnosis, higher hemoglobin and leukocyte levels, and increased rate of polycythemic transformation. In contrast, the mutation did not appear to affect the incidence of thrombotic, leukemic, or fibrotic events. There is increasing evidence regarding the thrombogenic role of neutrophils in essential thrombocythemia and this might partly explain the superior overall performance by hydroxyurea, compared with anagrelide, in a recent randomized study. Summary: Although it is in vogue to consider essential thrombocythemia as more than one disease in terms of both molecular phenotype (presence or absence of JAK2V617F) and putative pattern of myelopoiesis (monoclonal versus polyclonal), it is yet to be shown that such differences influence either the natural history of the disease or current therapy. From a treatment standpoint, hydroxyurea is now confirmed to be the drug of choice for high-risk patients with essential thrombocythemia.",
keywords = "Diagnosis, Hydroxyurea, JAK2, Thrombocythemia, Treatment",
author = "Ayalew Tefferi",
year = "2006",
month = "3",
doi = "10.1097/01.moh.0000208470.86732.b4",
language = "English (US)",
volume = "13",
pages = "93--98",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Essential thrombocythemia

T2 - Scientific advances and current practice

AU - Tefferi, Ayalew

PY - 2006/3

Y1 - 2006/3

N2 - Purpose of review: Median survival in essential thrombocythemia exceeds 20 years and clinical course is usually indolent with a minority of patients experiencing thrombohemorrhagic complications. Leukemic, polycythemic, or fibrotic disease transformation in essential thrombocythemia is an infrequent occurrence with a 15-year cumulative risk of approximately 5% or less in each instance. The major incentives for this review have been the recent description of an activating JAK2 tyrosine kinase mutation (JAK2V617F) in essential thrombocythemia, related myeloproliferative disorders, and the impact on clinical practice from the publication of a major treatment trial. Recent findings: Several studies have reported on the occurrence of JAK2 V617F in approximately 50% of patients with essential thrombocythemia and its presence has been associated with advanced age at diagnosis, higher hemoglobin and leukocyte levels, and increased rate of polycythemic transformation. In contrast, the mutation did not appear to affect the incidence of thrombotic, leukemic, or fibrotic events. There is increasing evidence regarding the thrombogenic role of neutrophils in essential thrombocythemia and this might partly explain the superior overall performance by hydroxyurea, compared with anagrelide, in a recent randomized study. Summary: Although it is in vogue to consider essential thrombocythemia as more than one disease in terms of both molecular phenotype (presence or absence of JAK2V617F) and putative pattern of myelopoiesis (monoclonal versus polyclonal), it is yet to be shown that such differences influence either the natural history of the disease or current therapy. From a treatment standpoint, hydroxyurea is now confirmed to be the drug of choice for high-risk patients with essential thrombocythemia.

AB - Purpose of review: Median survival in essential thrombocythemia exceeds 20 years and clinical course is usually indolent with a minority of patients experiencing thrombohemorrhagic complications. Leukemic, polycythemic, or fibrotic disease transformation in essential thrombocythemia is an infrequent occurrence with a 15-year cumulative risk of approximately 5% or less in each instance. The major incentives for this review have been the recent description of an activating JAK2 tyrosine kinase mutation (JAK2V617F) in essential thrombocythemia, related myeloproliferative disorders, and the impact on clinical practice from the publication of a major treatment trial. Recent findings: Several studies have reported on the occurrence of JAK2 V617F in approximately 50% of patients with essential thrombocythemia and its presence has been associated with advanced age at diagnosis, higher hemoglobin and leukocyte levels, and increased rate of polycythemic transformation. In contrast, the mutation did not appear to affect the incidence of thrombotic, leukemic, or fibrotic events. There is increasing evidence regarding the thrombogenic role of neutrophils in essential thrombocythemia and this might partly explain the superior overall performance by hydroxyurea, compared with anagrelide, in a recent randomized study. Summary: Although it is in vogue to consider essential thrombocythemia as more than one disease in terms of both molecular phenotype (presence or absence of JAK2V617F) and putative pattern of myelopoiesis (monoclonal versus polyclonal), it is yet to be shown that such differences influence either the natural history of the disease or current therapy. From a treatment standpoint, hydroxyurea is now confirmed to be the drug of choice for high-risk patients with essential thrombocythemia.

KW - Diagnosis

KW - Hydroxyurea

KW - JAK2

KW - Thrombocythemia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33646786143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646786143&partnerID=8YFLogxK

U2 - 10.1097/01.moh.0000208470.86732.b4

DO - 10.1097/01.moh.0000208470.86732.b4

M3 - Article

C2 - 16456375

AN - SCOPUS:33646786143

VL - 13

SP - 93

EP - 98

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -